Can Osteonecrosis of the Jaw Be Cured?

Osteonecrosis of the jaw can be treated, and in many cases the affected bone and soft tissue heal fully, but whether that counts as a “cure” depends on the severity of the disease, what caused it, and how aggressively it is managed. In a systematic review comparing surgical and nonsurgical approaches, roughly 62% of surgically treated patients achieved complete healing, while about 29% of conservatively treated patients did the same.¹ That gap tells a useful story: the condition is far from a death sentence for your jawbone, but it is not something that reliably clears up on its own either. The path to resolution depends on catching it early, choosing the right treatment strategy, and understanding the factors that make recurrence more or less likely.

What Osteonecrosis of the Jaw Actually Is

Osteonecrosis of the jaw means that part of the jawbone has lost its blood supply and the bone tissue has died. The condition most commonly develops as a side effect of medications, in which case it is called medication-related osteonecrosis of the jaw (MRONJ). The American Association of Oral and Maxillofacial Surgeons defines it based on a combination of your medication history and clinical findings such as exposed or prob-able bone that has persisted for at least eight weeks, with no history of radiation to the head or neck.² A separate form, osteoradionecrosis, develops after radiation therapy to the head and neck and is managed quite differently.

The drugs most often implicated are bisphosphonates (commonly prescribed for osteoporosis and bone metastases) and denosumab. Both work by slowing down the cells that break down old bone, which is helpful for strengthening the skeleton but can backfire in the jaw. The leading theory is that by suppressing these bone-remodeling cells, the drugs allow tiny fractures to accumulate in the jawbone without the normal repair process to fix them.³ Anti-angiogenic drugs used in cancer treatment can cause the same problem through a related mechanism: they interfere with the growth and survival of blood vessels, starving the bone tissue of its blood supply.⁴

Why Staging Matters for Prognosis

The chances of healing depend heavily on how advanced the disease is at diagnosis. MRONJ is staged from 0 (no exposed bone, but suspicious symptoms) through Stage 3 (exposed dead bone with infection spreading into surrounding tissue, sometimes causing pathologic fractures or fistulas). The widely used staging system developed by the AAOMS relies on clinical inspection and standard dental X-rays, but research has shown that these tools tend to underestimate how much bone is actually affected. CT imaging reveals more of the disease than a visual exam and a panoramic X-ray can.⁵ This matters for treatment planning because surgeons need to know the true boundary between dead and living bone. Advanced imaging such as contrast-enhanced MRI and PET/CT have been shown to detect more extensive disease than cone-beam CT or clinical examination alone.⁶ Three-dimensional imaging modalities like CT and cone-beam CT can reveal features that are relatively specific to MRONJ, including certain types of bone layering and cortical perforations that plain films miss.⁷

The upshot is that early-stage disease detected with good imaging has a much better outlook than late-stage disease that has been quietly spreading beneath the gumline. If you are on medications that carry MRONJ risk and develop new jaw symptoms, getting thorough imaging early gives you the best shot at a simpler treatment and a complete resolution.

Conservative Treatment and Its Limits

Conservative management typically means antibiotics, antimicrobial mouth rinses, pain control, and careful observation without surgery. For patients who cannot undergo surgery or who have very early-stage disease, this approach can keep symptoms manageable. But the evidence for long-term cure with conservative treatment alone is discouraging. In a long-term cohort study of 92 Stage 1 MRONJ lesions managed conservatively, only 8 achieved full mucosal coverage. Of the remaining 84, two-thirds worsened over time, and more than half eventually needed surgery.⁸ That same study noted that 28 lesions went on to develop severe bone destruction, even though the patients had stopped their bone-targeting medications after diagnosis.

Conservative care has a place: it can control pain, keep infection in check, and preserve quality of life for patients whose overall health makes surgery too risky. But the data suggests it should not be considered a curative strategy in most cases. Narrative reviews have acknowledged that while nonsurgical management shows “promising results in symptom control,” the absence of standardized treatment protocols remains a real limitation.⁹ The risk with relying solely on conservative care is silent disease progression: the bone continues to deteriorate under the gumline even when symptoms appear stable.

Surgical Treatment and Healing Rates

Surgery is where the numbers get more hopeful. One systematic review found disease resolution in about 70% of surgically treated patients compared with 36% of those managed without surgery.¹⁰ The type of surgery matters, too. A study comparing more aggressive surgical resection (removing a margin of healthy bone around the dead tissue) with simple debridement (scraping away loose bone fragments) found that debridement carried nearly five times the risk of recurrence compared to resection.¹¹ Patients who underwent resection also reported better quality of life over the following six months.

For severe cases where a large portion of the jaw must be removed, reconstructive surgery using free tissue flaps taken from other parts of the body (often the leg or shoulder blade) can rebuild the jaw. A systematic review of this approach in MRONJ patients found a flap success rate above 96%, with osteonecrosis recurring in only about 6% of cases afterward.¹² That is a serious surgery, but for patients facing advanced disease that has destroyed significant jaw structure, it represents a genuine path to functional recovery.

Even at Stage 3, surgery can make a transformative difference. In a study of 43 patients with the most severe form of MRONJ who underwent surgery, about 80% achieved full mucosal healing, and those who did not still improved enough to be reclassified as Stage 1.¹³ Quality-of-life scores improved by more than 50% after surgery, with gains in pain, swallowing, social eating, and the ability to open the mouth.

Adjunctive Therapies That May Improve Outcomes

Several add-on treatments have shown promise when combined with surgery, though none has become a universal standard yet.

Leukocyte and platelet-rich fibrin (L-PRF), a blood product prepared from the patient’s own blood and applied at the surgical site, has attracted significant interest. A meta-analysis found that combining L-PRF with surgical treatment of osteonecrosis yielded complete resolution in about 94% of cases, with relatively low variability across studies.¹⁴ These numbers are encouraging, though the only randomized controlled trial in this area found the advantage more modest, mainly showing benefits in early recovery speed, infection rate, and pain.¹⁵

Teriparatide, a synthetic form of parathyroid hormone that stimulates new bone formation, is arguably the most interesting pharmacological add-on. In a placebo-controlled randomized trial, about 45% of MRONJ lesions resolved by one year in the teriparatide group compared with roughly a third in the placebo group, and bone defects were significantly reduced.¹⁶ A smaller study found that after six months of teriparatide, every patient improved by at least one stage, and over a third achieved two stages of improvement or complete healing.¹⁷ Since teriparatide essentially reverses the bone-remodeling suppression that caused the problem in the first place, the biological rationale is strong. However, it is not suitable for all patients, particularly those with bone cancers, because stimulating bone growth in the presence of bone metastases could be harmful.

Hyperbaric oxygen therapy, which involves breathing pure oxygen in a pressurized chamber, has been reported to help in case reports and small series. The rationale is that flooding tissue with oxygen can support the growth of new blood vessels and boost the immune response in damaged bone.¹⁸ Case reports have documented successful outcomes when hyperbaric oxygen is used alongside standard treatment.¹⁹ However, a systematic review concluded that while hyperbaric oxygen shows benefit as a preventive measure in patients with a history of high-dose radiation to the jaw, the evidence for its effectiveness in treating existing osteonecrosis lesions surgically is less compelling.²⁰

Do Drug Holidays Help?

One of the most common questions patients ask is whether stopping their bisphosphonate or denosumab before or after a jaw problem develops will improve outcomes. The evidence is surprisingly discouraging. A meta-analysis found no significant difference in MRONJ development after tooth extraction between patients who took a drug holiday and those who did not.²¹ Holidays of 90, 120, or even 180 days did not improve treatment outcomes in another study.²²

The reason becomes clearer when you look at what is happening at the bone cell level. In a study of 30 patients who had been on oral bisphosphonates, osteoclasts (the cells that remodel bone) remained suppressed in about 87% of them regardless of how long the drug had been stopped. Even after six months or more off the medication, three out of four patients still showed suppressed osteoclast activity.²³ Bisphosphonates bind tightly to bone mineral and release slowly over years, which is why simply stopping the pills does not quickly reverse their effect on bone remodeling. This does not mean you should never discuss a drug holiday with your oncologist or endocrinologist, but it does mean you should not expect it to be a magic fix for ONJ.

The Role of Oral Bacteria

The jaw is uniquely vulnerable to osteonecrosis partly because it is the one bone in the body constantly exposed to bacteria through the teeth and gums. Research has shown that the oral microbiome plays a meaningful role in how the disease progresses. Bacterial genera including Actinomyces, Fusobacterium, and Streptococcus are commonly found in MRONJ lesions. These microbes promote inflammation and disrupt the already-compromised bone remodeling process.²⁴ This is why antimicrobial rinses and antibiotics are a standard part of both conservative and surgical treatment plans, and why keeping your mouth as clean as possible before and during treatment matters for outcomes.

Prevention Is More Effective Than Cure

The strongest message in the MRONJ literature is that prevention dramatically outperforms treatment. Patients who are about to start bisphosphonate or denosumab therapy should have a thorough dental examination first, with any necessary extractions, cavity treatments, or periodontal work completed before beginning the medication.²⁵ One study found that patients who did not receive comprehensive dental care before starting their medication had roughly 8.6 times the odds of developing MRONJ compared with those who did.²⁶ That is one of the most actionable numbers in this entire field. If you are prescribed one of these drugs, get your teeth sorted first.

How Radiation-Induced ONJ Differs

When osteonecrosis develops after radiation therapy to the head and neck rather than from medications, the management path diverges. Osteoradionecrosis tends to require more aggressive surgical treatment and is harder to manage conservatively. Surgical resection is performed significantly more often for radiation-induced disease, while minimal debridement is performed more often for medication-related disease.²⁷ In refractory cases of either type, the last-resort option is an extensive surgical resection with free flap reconstruction to rebuild the jaw, but the diseases cannot be managed with the same protocols.²⁸ If your ONJ developed after radiation, your treatment team will likely be more aggressive earlier, and your prognosis depends on different factors than medication-related disease.

Fluorescence-Guided Surgery

One of the more innovative developments in ONJ surgery involves using fluorescence to distinguish dead bone from living bone during the operation. The surgeon administers a dye (often tetracycline, an antibiotic that glows under ultraviolet light and only absorbs into living bone) before surgery. During the procedure, dead bone appears dark under UV light while living bone fluoresces, giving the surgeon a visual map of exactly what to remove. A systematic review of this technique found mucosal healing rates ranging from about 82% to 92%, with inflammation remission rates as high as 95%.²⁹ An alternative approach uses the bone’s own natural autofluorescence rather than a dye, and both methods produce similar results. Laser ablation guided by doxycycline fluorescence has also been explored as a minimally invasive option, with one case report showing regression from Stage 3 to nearly complete healing.³⁰ These techniques are still gaining traction and are not available everywhere, but they represent a meaningful step toward more precise surgery with potentially less healthy bone sacrificed in the process.

The Blood Test That Does Not Work

You may come across claims that a blood test measuring CTX (a marker of bone breakdown) can predict your risk of developing ONJ or guide your treatment. This idea gained popularity in the dental community, with some dentists requiring a CTX level below a certain threshold before performing extractions on bisphosphonate patients. The evidence does not support this practice. A meta-analysis found that the commonly cited CTX cutoff of 150 pg/mL had a sensitivity of only about 34% for predicting MRONJ, meaning it missed two out of three cases. The authors concluded that using CTX levels to assess MRONJ risk after dental procedures is not justified.³¹ A separate systematic review examining multiple biomarkers found that CTX was the most frequently studied but was only predictive in two out of six studies that tested it.³² If a dentist tells you they need to check your CTX level before pulling a tooth, it is worth knowing that the major professional guidelines no longer recommend this as a reliable predictor.

The Psychological Weight of Living With ONJ

The physical dimension of ONJ gets the most attention, but the mental health toll is significant and often overlooked. A controlled study comparing MRONJ patients to matched controls found significantly worse scores in physical functioning, bodily pain, and general health, which is not surprising. What stands out is that 64% of MRONJ patients showed symptoms of depression, compared with 16% of controls, and anxiety was reported in 16% of MRONJ patients versus none in the control group.³³ The condition affects your ability to eat, speak, and socialize comfortably. It can change how you look. And it usually occurs in people already dealing with cancer or osteoporosis, layering jaw problems on top of an already heavy burden. If you are struggling emotionally while managing ONJ, that is a clinically documented pattern, not a personal weakness, and it is worth raising with your care team.

The encouraging flipside is that successful treatment brings real psychological relief alongside the physical healing. Studies consistently show that surgical resolution of ONJ leads to significant improvements not only in pain and oral function but also in social eating, social contact, and overall mood.¹³ At one year after surgical treatment, one study found 100% mucosal healing and significant improvement across every quality-of-life domain measured.³⁴ The condition is treatable, and treating it meaningfully restores life quality, not just bone coverage.